BridgeMD
Tests treatment safety and results for Metastatic Colorectal Cancer
Official title A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
ClinicalTrials.gov ID: NCT06820463
What this study is testing
What is Telisotuzumab Adizutecan?
Telisotuzumab Adizutecan is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for metastatic colorectal cancer.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- CRC is the third most common type of cancer diagnosed worldwide with developed countries at highest risk. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given in combination with oxaliplatin, fluorouracil (5FU), leucovorin (LV) (FOLFOX), and bevacizumab or panitumumab.
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Laboratory values meeting the criteria within the protocol.
- Has measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1.
You likely can't join if
- Prior systemic regimen containing c-Met targeting agent(s) (e.g., antibody, antibody drug conjugate, bispecific) and/or any topoisomerase...
- History of other malignancies within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death.
The study team makes the final eligibility decision.
Where it's taking place
- Duarte, California, United States
- Santa Monica, California, United States
- New Haven, Connecticut, United States
- Chicago, Illinois, United States
- Hinsdale, Illinois, United States
- Boston, Massachusetts, United States
- Kansas City, Missouri, United States
- Omaha, Nebraska, United States
- Chapel Hill, North Carolina, United States
- Cincinnati, Ohio, United States
- Austin, Texas, United States
- Webster, Texas, United States
- Fairfax, Virginia, United States
- Seattle, Washington, United States
- Sydney, New South Wales, Australia
- South Brisbane, Queensland, Australia
- Woodville South, South Australia, Australia
- Heidelberg, Victoria, Australia
- Nedlands, Western Australia, Australia
- Vienna, Austria
+ 32 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Duarte, California, United States; Santa Monica, California, United States; New Haven, Connecticut, United States; Chicago, Illinois, United States; Hinsdale, Illinois, United States; Boston, Massachusetts, United States and 46 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.